Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

Journal of the American Heart Association

  ^{1    2    3    4    5    6    7} 

[1] Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN;Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN;Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN;Department of Emergency Medicine, Mayo Clinic, Rochester, MN;Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN;Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN;Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN;Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN;Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN;Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN;Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Scottsdale, AZ;Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN;Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN;Optum Labs, Cambridge, MA;

关键词: atrial fibrillation;    bleeding;    non–vitamin K antagonist oral anticoagulants;    stroke;    warfarin;   

DOI  :  10.1161/JAHA.116.003725

来源: publisher

【 授权许可】

Unknown